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Abstract
Background: A platinum doublet is the current standard treatment for good performance status patients with advanced
non-small cell lung cancer (NSCLC) and extensive stage small cell lung cancer (SCLC) with good performance status.
However, platinum-based treatment may be associated with significant toxicities, therefore alternative platinum-free
combinations should be investigated. Topotecan is a topoisomerase I inhibitor that exerts its cytotoxic effect through
stabilization of the topoisomerase I-DNA complex. Preclinical data suggests synergy between topoisomerase I inhibitors
and mitotic spindle poisons. Considerable hematologic toxicities have been reported with topotecan dosed for 5
consecutive days in combination with vinorelbine. Therefore, the aim of this study was to evaluate the optimal dosage
and the maximal tolerated dose (MTD) of topotecan and vinorelbine in patients with relapsed  or refractory non-small
cell or small cell lung cancer administered on  an alternate dosing schedule.
Methods: From February, 2004 to March, 2007 eighteen patients with advanced or recurrent NSCLC or SCLC
previously treated with chemotherapy were enrolled. Patients were heavily pretreated with 22% having received at least
3 prior lines of chemotherapy. Vinorelbine was administered at a fixed dose (20 mg/m2) and topotecan at escalating doses
(2, 2.5, 3, 3.5, and 4 mg/m2) on days 1 and 8 every 21 days.
Results: The MTD was not reached in any of the 5 cohorts, with only one dose limiting toxicity (DLT) occurring in
cohort 4. Non-hematological toxicities were manageable. One patient had a partial response with four patients (27%)
achieving stable disease. The median progression-free and overall survival for all patients, were 2.7 months (95% CI: 1.6,
9.1) and 10.5 months (95% CI: 4.2, 22.7), respectively.
Conclusion: Vinorelbine and topotecan administered on days 1 and 8 every 21 days is well tolerated without any DLT
seen with previously investigated topotecan schedules. This doublet provides a potentially active non-platinum containing
doublet for the treatment of patients with advanced SCLC and NSCLC. Vinorelbine and topotecan should therefore be
investigated in subsequent phase II studies at a dose of 20 mg/m2 and 4 mg/m2, respectively.
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Background
Advanced lung cancer remains a clinical challenge, with
median survival estimated in months, and one-year sur-
vival of less than 10% in patients treated with best sup-
portive care alone[1,2]. In patients with advanced non-
small cell lung cancer (NSCLC) single agent therapy with
cisplatin results in a modest clinical benefit and its use is
an independent prognostic variable predicting superior
survival[1,3]. The addition of a third generation cytotoxic
agent, including either vinorelbine, gemcitabine,
docetaxel or paclitaxel, to cisplatin results in improved
response rates and almost a doubling of 1-year survival
[3,4]. Multiple regimens have been compared, using a
platinum, either carboplatin or cisplatin, as one agent in
combination with another cytotoxic agent. In the ECOG
1594 trial, where patients with stage IV NSCLC were
treated with four different platinum containing doublets,
no significant differences in overall response rates or over-
all survival between them was observed [4]. Likewise, in
small cell lung cancer (SCLC) combination platinum
chemotherapy regimens are commonly utilized in part
due to their high response rates as first line therapy, par-
ticularly in patients with limited stage disease [5]. How-
ever, platinum-based treatment is associated with
significant toxicities, therefore development of alternative
platinum free chemotherapy combinations are warranted.
Topotecan is a topoisomerase I inhibitor that exerts its
cytotoxic effect through stabilization of the topoisomer-
ase I-DNA complex, thereby causing single-stranded DNA
breaks during replication [6]. Topotecan administered by
intravenous infusion daily for 5 days of a 21-day cycle at
a dose of 1.5 mg/m2 is an established treatment in recur-
rent small-cell lung cancer (SCLC) [7,8]. In second-line,
extensive stage SCLC, response rates (ORR) up to 22%
have been reported [5,9-11]. The standard 5-day topote-
can regimen approved for use in recurrent SCLC is also an
established treatment for relapsed ovarian cancer [12].
One of the drawbacks of the standard topotecan schedule
(1.5 mg/m2/day via a 30-minute i.v. injection on days 1–
5 of a 21-day cycle) is that it is associated with significant
myelosuppression with approximately 70% and 29% of
patients experiencing grade 4 neutropenia and thrombo-
cytopenia, respectively [2]. Myelosuppression is transient,
non-cumulative, and manageable, although approxi-
mately 5% of patients develop febrile neutropenia. The
major non-hematologic toxicities include fatigue, consti-
pation, and nausea/vomiting [13,14]. Weekly administra-
tion of topotecan has a different side effect profile with
less neutropenia, and also permits greater dose intensity
and thus greater ease of combining topotecan with other
anti-neoplastic agents [15,16].
Vinorelbine is a semi-synthetic vinca alkaloid; its most
common dose-limiting toxicity is neutropenia [17-19].
Vinorelbine is widely used in NSCLC where it has shown
considerable activity either as a single agent or in combi-
nation [19,20]. Vinorelbine has been studied in both pre-
viously treated and untreated patients with SCLC [18].
The rationale for combining topotecan and vinorelbine
for recurrent lung cancer is primarily based on single
agent activity and different toxicity profiles. Moreover,
preclinical data also suggests that topoisomerase I inhibi-
tors and mitotic spindle poisons are a synergistic combi-
nation [21]. This suggests that the combination of these
agents, both of which have independent activity in lung
cancer, would be of potential utility in the salvage setting.
Previous studies in patients with untreated SCLC or
NSCLC have evaluated weekly topotecan in combination
with other chemotherapeutic agents including: paclitaxel;
docetaxel; gemcitabine; temozolomide, oxaliplatin, cispl-
atin, and 5-FU/leucovorin [22-27]. Overall these studies
have demonstrated that weekly topotecan in combination
with various other cytotoxic agents could be safely admin-
istered to patients at doses between 1.5–4.5 mg/m2.
To date, two previously published phase I studies which
investigated escalating doses of daily topotecan in combi-
nation with vinorelbine, indicated that topotecan could
not be administered without filgrastim for 3 or 5 consec-
utive days at doses greater than 1.5 mg/m2 or 0.85 mg/m2,
respectively [28,29]. Therefore, a weekly dosing schedule
of both vinorelbine and topotecan warrants evaluation.
To our knowledge, no previous phase I study of escalating
doses of weekly topotecan, on days 1 and 8, in combina-
tion with a fixed dose of vinorelbine has been previously
published in patients with recurrent lung cancer (NSCLC
or SCLC). The purpose of this study therefore was to deter-
mine the maximum tolerated dose (MTD) of this chemo-
therapy doublet in patients with recurrent lung cancer.
Methods
Patients
The Protocol Review Committee of the Hollings Cancer
Center and the Medical University of South Carolina Insti-
tutional Review Board approved this study. A written
informed consent was obtained from all subjects. Patients
were enrolled from February, 2004 to March, 2007 at the
Medical University of South Carolina. Patients were
recruited based upon the following eligibility criteria:
pathologically proven lung cancer, all histologic types of
lung cancer were eligible (both small cell and non-small
cell lung cancer); recurrent or progressive disease after at
least one prior chemotherapy +/- radiotherapy regimen; at
least 2 weeks after completion of prior radiotherapy; no
prior therapy with topotecan or vinorelbine; age ≥ 18
years; ECOG performance status ≤ 2; adequate organ andBMC Cancer 2007, 7:231 http://www.biomedcentral.com/1471-2407/7/231
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marrow function defined as: absolute neutrophil count ≥
1,500/mm3, platelets ≥ 100,000/mm3, total bilirubin ≤
1.5 mg/dl, creatinine ≤ 1.5 mg/dl; non-pregnant and non-
lactating; no active concurrent invasive malignancy; abil-
ity to understand and the willingness to sign a written
informed consent document. Patients were excluded if
they: had chemotherapy within 4 weeks prior to entering
study; were currently receiving other investigational
agents; had a history of allergic reactions attributed to
compounds of similar chemical or biologic composition
to topotecan or vinorelbine; had uncontrolled intercur-
rent illness including active infection, symptomatic con-
gestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness.
Treatment and Dose Escalation
This was an open-label, single center, non-randomized,
dose escalating phase I study. Treatment was administered
on an outpatient basis. Topotecan and vinorelbine were
each administered on days 1 and 8 every 3 weeks [1 cycle
= 21 days] starting at doses of 20 mg/m2, and 2 mg/m2,
respectively. Doses of topotecan were increased, according
to a modified Fibonacci schedule, to 2.5, 3.0, 3.5, and 4.0
mg/m2 (Table 1). Vinorelbine was available in 1-ml or 5-
ml vials (10 mg/ml) and was diluted in any of the follow-
ing solutions: 5% dextrose, 0.9% sodium chloride, 0.45%
sodium chloride, 5% dextrose and 0.45% sodium chlo-
ride, Ringer's injection or lactated Ringer's injection.
Vinorelbine was administered prior to topotecan as a slow
IV push or rapid IV drip over 8–10 minutes. Topotecan
hydrochloride was available as 4 mg vials mixed with
mannitol and tartaric acid as excipients. It was then
diluted to either 0.025 mg/ml or 0.05 mg/ml in 0.9%
sodium chloride or 5% glucose. Topotecan was adminis-
tered over 30 minutes as an IV infusion subsequent to the
infusion of vinorelbine. Agents were administered into a
freely running intravenous line.
Assessment of response and toxicity
Toxicity was assessed using the NCI Common Toxicity
Criteria (version 2.0). If no patients during cycle 1 experi-
enced a dose limiting toxicity (DLT) at a given level, esca-
lation proceeded to the next dose level. A DLT was defined
as any grade 3–4 non-hematologic toxicity, grade 4 neu-
tropenia or thrombocytopenia. If one of three patients
had a DLT, then three additional patients were to be
enrolled in that cohort. If two or more patients had a DLT,
that dose was to be declared the Maximum Tolerated Dose
(MTD), and the next lower dose level was defined as the
recommended phase II dose.
Only those DLTs occurring during the first cycle of therapy
were used to define MTD. Those DLTs are described fol-
lows: Any documented grade 4 granulocytopenia or
thrombocytopenia; any documented ≥ grade 3 non-
hematologic toxicity (except grade 3 nausea or vomiting
or diarrhea in the first cycle but controlled to maximum of
grade 2 with anti-emetic or anti-diarrheal therapy in the
second cycle); inability to deliver any chemotherapy on
day 8 of cycle 1 because of ANC < 1000/ul or platelet
count < 50,000/ul; inability to begin the second cycle of
chemotherapy by day 35 because of persisting hemato-
logic or non-hematologic toxicity of ≥ grade 2 and possi-
bly, probably, or clearly due to therapy. Rates of
cumulative toxicity were monitored.
Patients received full supportive care measures. The rea-
son(s) for treatment delays and dosage adjustments, and
the dates of administration were recorded on flow sheets.
Treatment with hormones or other chemotherapeutic
agents was prohibited, unless steroids were given for adre-
nal failure or as intermittent use as anti-emetics. Palliative
radiation could not be administered during the treatment
protocol.
Statistical Methods
Time to event outcomes (progression-free survival and
overall survival) were analyzed using Kaplan-Meier
curves. Median survival estimates were derived and 95%
confidence intervals for median survival were calculated
using the Greenwood formula.
Duration of Therapy
Patients with stable or responding disease could continue
on therapy at the discretion of the treating physician. For
patients who had stable disease after one cycle, but during
that cycle experienced a DLT, subsequent protocol therapy
could be given at one dose level lower than their assigned
starting dose, and further dose reductions could be made.
Treatment could continue until disease progression, inter-
current illness that prevented further administration of
chemotherapy, unacceptable adverse events, patient deci-
sion to withdraw from study, or if general or specific
changes occurred in the patient rendering them unaccept-
able for further treatment in the judgment of the investi-
gator.
Table 1: Dose Escalation Schema.
Topotecan (mg/m2) Vinorelbine (mg/m2)
Level 1 2 20
Level 2 2.5 20
Level 3 3 20
Level 4 3.5 20
Level 5 4.0 20BMC Cancer 2007, 7:231 http://www.biomedcentral.com/1471-2407/7/231
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Treatment Assessment
Baseline evaluations were performed within four weeks of
beginning therapy using either CT or PET/CT scans. Labo-
ratory evaluation was performed weekly during cycle one,
and then on days 1 and 8 of all subsequent cycles.
Response and progression was determined by using the
Response Evaluation Criteria in Solid Tumors (RECIST).
All measurements were recorded in metric notation; imag-
ing to assess response to therapy was obtained every two
cycles.
Results
Eighteen patients with recurrent NSCLC or SCLC were
included in this phase I study between February 2004 and
March 2007. Patient characteristics are listed in Table 2.
The majority of patients were either asymptomatic or had
only mild symptoms. There were nine female and nine
male patients. Most of the patients had received at least
two primary chemotherapy regimens; only six patients
had previously received radiation therapy. All patients
had received prior platinum-based chemotherapy, and all
but one patient with NSCLC had previously received tax-
anes. Overall patients enrolled in this study were heavily
pretreated with 11/18 patients having received at least 3
prior lines of chemotherapy. The most common tumor
type was NSCLC (n = 15), with three patients having
recurrent SCLC. The total number of assessable cycles was
75, with the median number of cycles per cohort listed in
Table 3.
Hematologic Toxicities
Neutropenia was the most commonly observed grade 3–
4 hematologic toxicity, with grade 4 neutropenia occur-
ring in 3 out of 75 total chemotherapy cycles administered
(4%). Anemia was frequent, with all events being ≤ grade
2. Thrombocytopenia was also observed, however all
events were ≤ grade 2. Febrile neutropenia was reported in
one patient in cohort 3 during cycle 4, resulting in hospi-
tal admission and treatment with intravenous antibiotics.
The MTD was not reached in any of the 5 cohorts. The
hematologic toxicity profile is listed in Table 3.
Non-hematologic Toxicities
There was no evidence of any severe grade 3–4 non-hema-
tologic toxicities in this study (Table 3). The most frequent
non-hematologic adverse toxicities with combination
vinorelbine/topotecan were grade 1–2 nausea/vomiting,
fatigue, constipation, and neuropathy (Table 4). One
patient in cohort 2 was taken off of study due to grade 3
fatigue following one cycle of therapy. Transient eleva-
tions in hepatic transaminases were also observed in dif-
ferent cohorts. Additional clinically relevant toxicities
included febrile illness without neutropenia in three
patients, and hyperglycemia in nine patients. Due to the
overall tolerability of vinorelbine and topotecan, there
were few dose delays with subsequent chemotherapy
cycles.
Anti-tumor Activity of vinorelbine/topotecan
Fifteen patients were evaluable for tumor response. Only
one objective tumor response was observed (partial
response); additionally four patients achieved stable dis-
ease for ≥ 6 cycles of therapy (Table 5). All patients with
stable disease had NSCLC and were heavily pretreated
(mean number of previous therapies = 3). Of these
patients, one was in cohort 2, two were in cohort 3 and
one was in cohort 4. The median follow-up time was 9.4
months. The median progression-free survival and overall
survival for all patients were 2.7 months (95% CI: 1.6,
9.1) and 10.5 months (95% CI: 4.2, 22.7), respectively.
Figures 1 and 2 demonstrate Kaplan-Meier curves for both
progression-free and overall survival, respectively.
Discussion
Doublet chemotherapy is considered a standard of care
for good performance status patients with stage IV NSCLC
and extensive stage SCLC; however options for doublet
combinations are still limited [4,5,7]. Additional non-
platinum and non-taxane doublets are therefore needed.
Vinorelbine is well established as an active drug in non-
small cell lung cancer, and topotecan is the standard of
care for second line therapy for small cell lung cancer. The
use of vinorelbine in combination therapy has demon-
strated efficacy, particularly in combination with cispla-
tin. Weekly administration of topotecan has improved
Table 2: Patient Characteristics.
Characteristics n
Age (years)
Median 64
Range 49–77
Gender
Male 9
Female 9
ECOG performance status
05
11 2
21
Not Reported 3
Tumor Type
NSCLC 15
SCLC 3
Previous Chemotherapy Regimens
15
22
35
≥46
Prior Radiotherapy 6BMC Cancer 2007, 7:231 http://www.biomedcentral.com/1471-2407/7/231
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Table 3: Hematologic toxicities. Observed toxicities with vinorelbine/topotecan during all cycles of chemotherapy.
Cohort N = Treatment 
cycles 
(median)
Neutropenia Thrombocytopenia Anemia
Grade 1–2 Grade 3 Grade 4 FN Grade 1–2 Grade 3–4 Grade 1–2 Grade 3–4
13 1 2  ( 4 ) 10000070
23 1 1  ( 4 ) 90001030
33 1 8  ( 6 ) 96 2 * 1 * 40 1 0 0
46 2 2  ( 4 ) 781070 1 4 0
53 1 2  ( 4 ) 20002030
* Occurred after cycle 1. Abbreviations: FN: febrile neutropenia.
Table 4: Non-hematologic toxicities. All toxicities were grade 1–2 unless otherwise specified.
Cohort N = Treatment 
cycles 
(median)
Fatigue Nausea/
vomiting
Constipa
tion
Alk Phos Cough/
Dyspnea
Hypo-
kalemia
Hyper-
glycemia
↑ LFTs Diarrhea Neuropathy
1 3 1 2  ( 4 ) 2 121012 0 1 1
23 1 1  ( 4 ) 2 § 410003 1 1 2
3 3 1 8  ( 6 ) 6 823 4 * * 14 2 0 1
4 6 2 2  ( 4 ) 6 271112 1 0 0
5 3 1 2  ( 4 ) 1 310000 0 0 4
§One patient with grade 4 fatigue. **One patient with grade 4 respiratory failure requiring intubation during cycle 2 only.
Table 5: Best Response Rates by cohort.
Cohort Progressive Disease Stable Disease Partial Response Complete Response
13 0 0 0
22 1 0 0
31 2 0 0
45 1 0 0
52 0 1 0BMC Cancer 2007, 7:231 http://www.biomedcentral.com/1471-2407/7/231
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tolerability over daily administration [2]. Tolerability of
both vinorelbine and topotecan has been well established
in advanced lung cancer as single agents [3,13,14]. The
different toxicity profiles of vinorelbine and topotecan
supports the use of these agents as a non-platinum dou-
blet. Two previous phase I studies have explored the MTD
of vinorelbine and topotecan utilizing different schedules
than our study. Stupp and colleagues, treated newly diag-
nosed patients with recurrent or metastatic NSCLC as first-
line therapy with topotecan (0.5–1.0 mg/m2 days 1–5)
and vinorelbine (20–30 mg/m2 days 1 and 5) in 21-day
cycles. Dose-limiting toxicity (DLT) was defined sepa-
rately with or without the addition of filgrastim. Neutro-
penia was frequent but transient. Without G-CSF support,
the MTD of topotecan was 0.85  mg/m2, with neutropenic
fever being the DLT. With the addition of G-CSF,  the MTD
was not reached. Non-hematologic toxicities included
mild to moderate fatigue and constipation. An overall
clinical response rate of 42% was achieved, with responses
noted at all dose levels. At a short median follow-up of 15
months, the median survival for all patients was 13
months [29]. In a subsequent phase I trial by Hanna and
colleagues, patients with advanced solid tumors with no
more than 1 prior chemotherapy regimen were treated
with topotecan (1.5 mg/m2 days 1–3) followed by vinor-
elbine (25 mg/m2 days 1 and 8) without filgrastim every 3
weeks [28]. At this first dose level all three patients experi-
enced hematologic DLT including grade 4 neutropenia
grade 3 thrombocytopenia. An additional 2 patients were
treated at this same dose level but received prophylactic
filgrastim, however both also had DLT. Consequently,
alternative schedules to consecutive daily administration
of topotecan should be explored both as a single agent
and in combination with other agents [16]. To our knowl-
edge, no prior phase I study has been published that
investigated the MTD of weekly vinorelbine and topote-
can (days 1 and 8) in patients with advanced cancer.
Results from our trial suggest that vinorelbine/topotecan
on days 1 and 8 every 21 days is well tolerated. The pri-
mary DLT is neutropenia with no grade 3–4 non-hemato-
logic toxicities.
Conclusion
As the MTD was not achieved in the 5 different dose levels
of topotecan in our study, we therefore conclude that the
recommended phase II dose for vinorelbine and topote-
can, on this particular schedule, is 20 mg/m2and 4 mg/m2,
respectively. Future studies of vinorelbine and topotecan
in advanced SCLC and NSCLC are warranted and may
provide a better-tolerated alternative to platinum based
doublets.
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Overall Survival Figure 2
Overall Survival. Median overall survival for patients in all 
cohorts was 10.5 months (95% CI, 4.2 to 22.7)
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Progression-Free Survival Figure 1
Progression-Free Survival. Median progression free sur-
vival for patients in all cohorts was 2.7 months (95% CI, 1.6 
to 9.1).
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